Celastrol, a novel HSP90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation

This publication has 32 references indexed in Scilit:

• Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
  Journal of Clinical Investigation, 2009
• Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
  Leukemia, 2008
• A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
  Molecular Cancer Therapeutics, 2008
• Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma
  Clinical Cancer Research, 2007
• Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials
  Cell, 2007
• Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells
  Blood, 2007
• Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB–regulated gene products and TAK1-mediated NF-κB activation
  Blood, 2006
• A Sequential Blockade Strategy for the Design of Combination Therapies to Overcome Oncogene Addiction in Chronic Myelogenous Leukemia
  Cancer Research, 2006
• Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance
  Blood, 2006
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
  Science, 2001